Journal
CURRENT OPINION IN CHEMICAL BIOLOGY
Volume 14, Issue 4, Pages 467-474Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.cbpa.2010.06.176
Keywords
-
Categories
Funding
- Northeast Biodefense Center [AI057158]
- Rocky Mountain Regional Center of Excellence [AI065357]
- National Institutes of Health [AI044639, AI070383]
Ask authors/readers for more resources
Failure due to poor in vivo efficacy is a primary contributor to attrition during the development of new chemotherapeutics. Lead optimization programs that in their quest for efficacy focus solely on improving the affinity of drug-target binding are flawed, since this approach ignores the fluctuations in drug concentration that occur in vivo. Instead the lifetime of the drug-target complex must also be considered, since drugs only act when they are bound to their targets. Consequently, to improve the correlation between the in vitro and in vivo activity of drugs, measurements of drug-target residence time must be incorporated into the drug discovery process.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available